Rani Therapeutics Holdings, Inc. (RANI)
↓ Download CSV- Sector Manufacturing
- Incorporated CA
- Fiscal year ends Dec 31
In fiscal 2025, Rani Therapeutics Holdings, Inc. reported revenue of $1.63M, up 58.9% from the prior year. The company ran a net loss, with a net margin of -2507.7%. It held $58.62M in total assets against $17.11M in total liabilities.
Key ratios (FY2025)
-2346.0%
Operating margin
-2507.7%
Net margin
-124.1%
Return on equity
+58.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.63M | $1.03M | $0 | $0 | $2.72M | $462.0K |
| Operating Income | -$38.31M | -$53.31M | -$66.10M | -$63.45M | -$51.60M | -$16.54M |
| Net Income | -$40.95M | -$56.58M | -$67.88M | -$63.34M | -$53.09M | -$16.70M |
| EPS (Diluted) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 | — |
| Total Assets | $58.62M | $36.63M | $57.92M | $108.03M | $124.21M | $79.42M |
| Total Liabilities | $17.11M | $33.14M | $32.47M | $34.02M | $2.64M | $8.04M |
| Shareholders' Equity | $33.01M | $1.99M | $12.87M | $36.85M | $47.41M | -$113.34M |
| Cash & Equivalents | $18.62M | $3.76M | $5.86M | $27.01M | $117.45M | $73.06M |
| Operating Cash Flow | -$18.71M | -$35.50M | -$51.24M | -$46.52M | -$32.24M | -$14.96M |
| Capital Expenditures | $88.0K | $268.0K | $1.23M | $1.62M | $506.0K | $1.20M |
| Shares Outstanding | 66.1K | 28.5K | 25.5K | 23.8K | 19.5K | — |